Evaluation of von Willebrand Factor and von Willebrand Factor Propeptide in Models of Vascular Endothelial Cell Activation, Perturbation, and/or Injury

Toxicologic Pathology

Volumn 42, Issue 4, 2014, Pages 672-683

  Brott, David A ^a   Katein, Anne ^a   Thomas, Heath ^b   Lawton, Michael ^c   Montgomery, Robert R ^d   Richardson, Rudy J ^e   Louden, Calvert S ^f   Morton, Daniel ^f   Tomlinson, Lindsay ^f  

^a ASTRAZENECA   (United Kingdom)

^b Safety Assessment   (United States)

^c PFIZER INC   (United States)

^d BLOOD RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f API Large Molecule Pharmaceutical Development and Manufacturing Sciences   (United States)

Author keywords

activation; biomarker; DDAVP; DIVI; dog; endothelial cell; LPS; perturbation; rat; VWF; VWFpp

Indexed keywords

AMIDE; BENZOPHENONE DERIVATIVE; BIOLOGICAL MARKER; DOPAMINE; FENOLDOPAM; PROTEIN PRECURSOR; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR PROPOLYPEPTIDE; ZENECA ZD 6169; ENDOTOXIN; LIPOPOLYSACCHARIDE; N (4 BENZOYLPHENYL) 3,3,3 TRIFLUORO 2 HYDROXY 2 METHYLPROPIONAMIDE; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR PROPEPTIDE;

ADVERSE DRUG REACTION; ANIMAL; BLOOD; DOG; DRUG EFFECTS; ENDOTHELIUM CELL; FEMALE; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHLEBOTOMY; RAT; THROMBOCYTE; VASCULAR SYSTEM INJURIES; WISTAR RAT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CELL ACTIVATION; CELL DAMAGE; CELL LEVEL; CELL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDUCED VASCULAR INJURY; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; VASCULAR ENDOTHELIUM;

ADMINISTRATION, ORAL; AMIDES; ANIMALS; BENZOPHENONES; BIOMARKERS; BLOOD PLATELETS; DOGS; DOPAMINE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDOTHELIAL CELLS; FEMALE; FENOLDOPAM; MALE; PHLEBOTOMY; PROTEIN PRECURSORS; RATS; RATS, WISTAR; VASCULAR SYSTEM INJURIES; VON WILLEBRAND FACTOR;

EID: 84902078130     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623313518664     Document Type: Article

References (46)

1. Blann A. D. (2006). Plasma von Willebrand factor, thrombosis, and the endothelium: The first 30 years. Thromb Haemost 95, 49–55.
2. Borchiellini A. Fijnvandraat K. ten Cat J. W. Pajkrt D. van Deventer S. J. Pasterkamp G. Meijer-Huizinga F. Zwart-Huinink L. Voorberg J. van Mourik J. A. (1996). Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 88, 2951–8.
3. Brott D. Gould S. Jones H. Schofield J. Prior H. Valentin J. P. Bjurstrom S. Kenne K. Schuppe-Koistinen I. Katein A. Foster-Brown L. Betton G. Richardson R. Evans G. Louden C. (2005). Biomarkers of drug-induced vascular injury. Toxicol Appl Pharmacol 207, S441–S5.
4. Brott D. A. Richardson R. J. Louden C. S. (2012). Evidence for the nitric oxide pathway as a potential mode of action in fenoldopam-induced vascular injury. Toxicol Pathol 40, 874–86.
5. Castro-Nŭnez L. Dienava-Verdoold I. Herczenik E. Mertens K. Meijer A. B. (2012). Shear stress is required for the endocytic uptake of the factor VIII-von Willebrand factor complex by macrophages. J Thromb Haemost 10, 1929–37.
6. Fujisawa T. Takagi J. Sekiya F. Goto A. Miake F. Saito Y. (1991). Monoclonal antibodies that inhibit binding of propolypeptide of von Willebrand factor to collagen, localization of epitopos. Eur J Biochem 196, 673–7.
7. Giblin J. P. Hewlett L. J. Hannah M. J. (2008). Basal secretion of von Willebrand factor from human endothelial cells. Blood 112, 957–64.
8. Greaves P. (1998). Patterns of drug-induced cardiovascular pathology in the beagle dog: Relevance for humans. Exp Toxicol Pathol 50, 283–93.
9. Jahroudi N. Ardekani A. M. Greenberger J. S. (1996). Ionizing irradiation increases transcription of the von Willebrand factor gene in endothelial cells. Blood 88, 3801–14.
10. Jahroudi N. Lynch D. C. (1994). Endothelial-cell-specific regulation of von Willebrand factor gene expression. Mol Cell Biol 14, 999–1008.
11. Jones H. B. Bjökman J. A. Schofield J. (2013). Coronary and systemic arterial physiology and immunohistochemical markers related to early coronary arterial lesions in beagle dogs given the PCO, ZD6169, or endothelin receptor antagonist, ZD1611. Toxicol Pathol 41, 722–35.
12. Kanwar S. Woodman R. C. Poon M. C. Murohara T. Lefer A. M. Davenpeck K. L. Kubes P. (1995). Desmopressin induces endothelial p-selectin expression and leukocyte rolling in postcappillary venules. Blood 86, 2760–6.
13. Kerns W. D. Arena E. Macia R. A. Bugelski P. J. Matthews W. D. Morgan D. G. (1989a). Pathogenesis of arterial lesions induced by dopaminergic compounds in the rat. Toxicol Pathol 17, 203–13.
14. Kerns W. D. Arena E. Morgan D. G. (1989b). Role of dopaminergic and adrenergic receptors in the pathogenesis of arterial lesions induced by fenoldopam mesylate and dopamine in the rat. Am J Pathol 135, 339–49.
15. Louden C. Brott D. Katein A. Kelly T. Gould S. Jones H. Betton G. Valentin J. P. Richardson R. (2006). Biomarkers and mechanisms of drug-induced vascular injury in non-rodents. Toxicol Pathol 34, 19–26.
16. Louden C. Morgan D. G. (2001). Pathology and pathophysiology of drug-induced arterial injury in laboratory animals and its implications on the evaluation of novel chemical entities for human clinical trials. Pharmacol Toxicol 89, 158–70.
17. Louden C. S. Nambi P. Pullen M. A. Thomas R. A. Tierney L. A. Solleveld H. A. Schwartz L. W. (2000). Endothelin receptor subtype distribution predisposes coronary arteries to damage. Am J Pathol 157, 123–34.
18. Lundin S. Vilhardt H. (1986). Absorption of intragastrically administered DDAVP in conscious dogs. Life Sci 38, 703–9.
19. McCarrol D. R. Waters D. C. Steidley K. R. Clift R. McDonald T. P. (1988). Canine platelet von Willebrand factor: Quantification and multimeric analysis. Exp Hematol 16, 929–37.
20. McFarland D. C. Scicchitano M. S. Thomas R. A. Narayanan P. K. Schwartz L. W. Thomas H. C. (2004). 6-color flow-sorting of rat circulating endothelial cells and taqman® real-time PCR analysis. Cytometry 59A, 65.
21. Meigs J. B. O’Donnell C. J. Tofler G. H. Benjamin E. J. Fox C. S. Lipinska I. Nathan D. M. Sullivan L. M. D’Agostino R. B. Wilson P. W. (2006). Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: The Framingham offspring study. Diabetes 55, 530–7.
22. Mesfin G. M. Piper R. C. DuCharme D. W. Carlson R. G. Humphrey S. J. Zins G. R. (1989). Pathogenesis of cardiovascular alterations in dogs treated with minoxidil. Toxicol Pathol 17, 164–81.
23. Meyers K. M. Boehme M. Inbar O. (1982). Binding of 124I-labeled endotoxin to bovine, canine, and equine platelets and endotoxin-induced agglutination of canine platelets. Am J Vet Res 43, 1721–8.
24. Montgomery R. R. Gill J. C. (2000). Interactions between von Willebrand factor and Factor VIII: Where did they first meet? J Pediatr Hematol Oncol 22, 269–75.
25. Newsholme S. J. Thudium D. T. Gossett K. A. Watson E. S. Schwartz L. W. (2000). Evaluation of plasma von Willebrand factor as a biomarker for acute arterial damage in rats. Toxicol Pathol 28, 688–93.
26. Nichols T. C. Samama C. M. Bellinger D. A. Roussi J. Reddick R. L. Bonneau M. Read M. S. Bailliart O. Kockh G. G. Vaiman M. (1995). Function of von Willebrand factor after crossed bone marrow transplantation between normal and von willibrand disease pigs: Effect on arterial thrombosis in chimeras. Proc Natl Acad Sci USA 92, 2455–9.
27. Nightingale T. Cutler D. (2013). The secretion of von Willebrand factor from endothelial cells: An increasingly complicated story. J Thromb Haemost 11, 192–201.
28. Olsen E. H. McCain A. S. Merricks E. P. Fischer T. H. Dillon I. M. Raymer R. A. Bellinger D. A. Fahs S. A. Montgomery R. R. Keith J. C. Jr Schaub R. G. Nichols T. C. (2003). Comparative response of plasma VWF in dogs to upregulation of VWF mRNA by interleukin-11 versus Weibel–Palade body release by Desmopressin (DDAVP). Blood 102, 436–41.
29. Ruggeri Z. M. (1991). Structure and function of von Willebrand factor: Relationship to von Willebrand’s disease. Mayo Clin Proc 66, 847–61.
30. Sanders W. E. Jr Reddick R. L. Nichols T. C. Brinkhous K. M. Read M. S. (1995). Thrombotic thrombocytopenia induced in dogs and pigs. The role of plasma and platelet vwf in animal models of thrombotic thrombocytopenia purpura. Arterioscler Thomb Vasc Biol 15, 793–800.
31. Scicchitano M. Thomas R. McFarland D. Narayanan P. Thomas H. Tierney L. Schwartz L. (2003). Transcriptional phenotyping of circulating endothelial cells form sorted rat whole blood. Vet Pathol 40, 626a.
32. Sporn L. A. Marder V. J. Wagner D. D. (1987). Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells. J Cell Biol 108, 1283–9.
33. Suffredini A. F. Fromm R. E. Parker M. M. Brenner M. Kovacs J. A. Wesley R. A. Parrillo J. E. (1989). The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321, 280–7.
34. Usui T. Takagi J. Saito Y. (1993). Propolypeptide of von Willebrand factor serves as a substrate for factor XIIIa and is cross-linked to laminin. J Biol Chem 268, 12311–6.
35. Van Buul-Wortelboer M. F. Brinkman H. J. Reinders J. H. van Aken W. G. van Mourik J. A. (1989). Polar secretion of von Willebrand factor by endothelial cells. Biochim Biophys Acta 1011, 129–33.
36. Van Deventer S. J. Büller H. R. ten Cate J. W. Aarden L. A. Hack C. E. Sturk A. (1990). Experimental endotoxemia in human: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76, 2520–6.
37. van Mourik J. A. Boertjes R. Huisveld I. A. Fijnvandraat K. Pajkrt D. van Genderen P. J. Fijnheer R. (1999). von Willebrand factor in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation. Blood 94, 179–85.
38. van Mourik J. A. Romani de Wit T. (2001). von Willebrand factor propeptide in vascular disorders. Thromb Haemost 86, 164–71.
39. Vischer U. M. Ingerslev J. Wollheim C. B. Mestries J. C. Tsakiris D. A. Haefeli W. E. Kruithof E. K. (1997). Acute von Willebrand factor secretion from the endothelium in vivo: Assessment through plasma propeptide (VWF:AgII) levels. Thromb Haemost 77, 387–93.
40. Vischer U. M. Wagner D. D. (1994). von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood 83, 3536–44.
41. Wagner D. D. Fay P. J. Sporn L. A. Sinha S. Lawrence S. O. Marder V. J. (1987). Divergent fates of von Willebrand factor and its proplypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci USA 84, 1955–9.
42. Ware L. B. Eisner M. D. Thompson B. T. Parsons P. E. Matthay M. A. (2004). Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med 170, 766–72.
43. Weibel E. R. Palade G. E. (1964). New cytoplasmic components in arterial endothelia. J Cell Biol 23, 101–12.
44. Weibel E. R. (2012). Fifty years of Weibel-Palade bodies: The discovery and early history of an enigmatic organelle of endothelial cells. J Thromb Haemost 10, 979–84.
45. Yuhas E. M. Morgan D. G. Arena E. Kupp R. P. Saunders L. Z. Lewis H. B. (1985). Arterial medial necrosis and hemorrhage induced in rats by intravenous infusion of fenoldopam mesylate, a dopaminergic vasodilator. Am J Pathol 119, 83–91.
46. Zhang J. Defelice A. F. Hanig J. P. Colatsky T. (2010). Biomarkers of endothelial cell (EC) activation serve as potential surrogate markers for drug-induced vascular injury. Toxicol Pathol 38, 856–71.